Soluble Vascular Adhesion Protein 1 (sVAP-1) as a biomarker for pregnancy complications: A pilot study.
Soluble Vascular Adhesion Protein 1 (sVAP-1) as a biomarker for pregnancy complications: A pilot study.
复制标题
DOI：
10.1371/journal.pone.0284412
复制
发表时间：
2023
期刊：
影响因子：
3.7
通讯作者：
Tan, Bee Kang
中科院分区：
文献类型：
--
作者：
Danielli, Marianna;Thomas, Roisin C.;Gillies, Clare L.;Lambert, David G.;Khunti, Kamlesh;Tan, Bee Kang
血管黏附蛋白1（VAP - 1）与多种临床病症有关。此外，在一些临床研究中，血清水平与疾病的预测和进展相关。关于VAP - 1与妊娠的数据很少。鉴于VAP - 1在妊娠中的新作用，本研究的目的是检验可溶性血管黏附蛋白1（sVAP - 1）作为妊娠并发症，尤其是妊娠期高血压的早期生物标志物。本研究的目标是将sVAP - 1水平与其他妊娠并发症、患者人口统计学特征以及整个妊娠期进行的血液检测相关联。
我们在英国莱斯特皇家医院（LRI）进行首次产前超声检查的一组孕妇（招募时孕周小于20周）中进行了一项试点研究。数据既有前瞻性生成的（来自血液样本分析），也有回顾性收集的（来自医院记录）。
2021年7月至10月期间，共有91名参与者入组。通过酶联免疫吸附测定（ELISA），我们发现患有妊娠高血压（PIH）（310 ng/mL）或妊娠期糖尿病（GDM）（366.73 ng/mL）的孕妇血清sVAP - 1水平相较于对照组（分别为427.44 ng/mL和428.34 ng/mL）降低。胎儿生长受限（FGR）女性与对照组之间未发现显著差异（424.32 ng/mL对424.52 ng/mL），有任何妊娠并发症的患者与健康妊娠相比也无显著差异（421.28 ng/mL对428.34 ng/mL）。
需要进一步研究以确定sVAP - 1是否可被视为一种早期、无创且价格合理的生物标志物，用于筛查将会发生PIH或GDM的女性。我们的数据将有助于此类更大规模研究的样本量计算。
Vascular adhesion protein 1 (VAP-1) has been implicated in a wide range of clinical conditions. Moreover, serum levels are associated with disease prediction and progression in several clinical studies. There is a paucity of data on VAP-1 and pregnancy. Given the emerging role of VAP-1 in pregnancy, the aim of this study was to examine sVAP-1 as an early biomarker of pregnancy complications, especially hypertension during pregnancy. The objectives of the study are to associate sVAP-1 levels with other pregnancy complications, patient demographics and blood tests performed throughout pregnancy. We conducted a pilot study in a cohort of pregnant women (gestational week lower than 20 at the time of recruitment) attending their first antenatal ultrasound scan at the Leicester Royal Infirmary (LRI, UK). Data were both prospectively generated (from blood sample analysis) and retrospectively collected (from hospital records). From July and October 2021, a total of 91 participants were enrolled. Using ELISA (enzyme-linked immunosorbent assay), we found reduced serum levels of sVAP-1 in pregnant women with either pregnancy induced hypertension (PIH) (310 ng/mL) or GDM (366.73 ng/mL) as compared to controls (427.44 ng/mL and 428.34 ng/mL, respectively). No significant difference was found between women with FGR compared to controls (424.32 ng/mL vs 424.52 ng/mL), and patients with any pregnancy complications compared to healthy pregnancies (421.28 ng/mL vs 428.34 ng/mL). Further studies are needed to establish whether or not sVAP-1 might be considered as an early, non-invasive, and affordable biomarker to screen women who will develop PIH or GDM. Our data will aid sample size calculations for such larger studies.
登录
查看更多内容
DOI：
10.4021/jocmr1682w
发表时间：
2014-02
期刊：
Journal of clinical medicine research
影响因子：
--
作者：
Al-Jameil N;Aziz Khan F;Fareed Khan M;Tabassum H
通讯作者：
Tabassum H
用于预测先兆子痫的新型生物标志物。
影响因子：
9.3
作者：
Carty, David M.;Delles, Christian;Dominciczak, Anna F.
通讯作者：
Dominciczak, Anna F.
影响因子：
3.7
作者：
Li HY;Lin HA;Nien FJ;Wu VC;Jiang YD;Chang TJ;Kao HL;Lin MS;Wei JN;Lin CH;Shih SR;Hung CS;Chuang LM
通讯作者：
Chuang LM
影响因子：
4
作者：
Danielli, Marianna;Thomas, Roisin C.;Gillies, Clare L.;Hu, Jiamiao;Khunti, Kamlesh;Tan, Bee Kang
通讯作者：
Tan, Bee Kang
影响因子：
5.5
作者：
Gharanei S;Fishwick K;Peter Durairaj R;Jin T;Siamantouras E;Liu KK;Straube A;Lucas ES;Weston CJ;Rantakari P;Salmi M;Jalkanen S;Brosens JJ;Tan BK
通讯作者：
Tan BK